Quick Summary
Additional Context
PharmaTher Holdings is building a range of 3D printed peptide products for a new U.S. compounding pathway. The first two are oral tablets of KPV and BPC-157 designed to release their dose in the colon. It is timed to the U.S. Department of Health and Human Services (HHS) policy that lets qualified Section 503A pharmacies compound six named peptides under conditions. KPV and BPC-157 are the only two of the six cleared for oral use.
Both products are built on PharmaTher’s M3DICINES platform. They use CORR3CT (COntRollable Release in 3D printed Colonic Targeting), a patent-pending technology from Singapore-based Craft Health. The tablets are designed to pass through the stomach intact and release the peptide in the colon. PharmaTher is aiming them at gastrointestinal conditions where deliver